Arrowstreet Capital Limited Partnership Trims Stake in Amneal Pharmaceuticals, Inc. $AMRX

Key Points

• Arrowstreet Capital cut its Amneal Pharmaceuticals stake by 51.9% in the first quarter, selling 566,457 shares and retaining 523,967 shares worth approximately $6.5 million.
• Amneal reported stronger-than-expected second-quarter results, including approximately $796 million in revenue, $206 million in adjusted EBITDA and adjusted EPS of $0.30. Management also raised 2026 revenue guidance to $3.1 billion–$3.2 billion, while a debt repricing is expected to reduce interest costs.
• Analysts remain broadly bullish, with seven Buy ratings and one Hold rating, an average “Moderate Buy” consensus and an average price target of $17.33. Shares opened at $18.32, near the company’s 52-week high of $19.26.

Arrowstreet Capital Limited Partnership lowered its position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 51.9% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 523,967 shares of the company's stock after selling 566,457 shares during the period. Arrowstreet Capital Limited Partnership owned approximately 0.17% of Amneal Pharmaceuticals worth $6,513,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also modified their holdings of AMRX. Kemnay Advisory Services Inc. bought a new stake in shares of Amneal Pharmaceuticals during the 4th quarter worth approximately $26,000. Federated Hermes Inc. grew its position in Amneal Pharmaceuticals by 1,680.6% in the 4th quarter. Federated Hermes Inc. now owns 2,297 shares of the company's stock valued at $29,000 after acquiring an additional 2,168 shares during the last quarter. Spire Wealth Management grew its position in Amneal Pharmaceuticals by 66.6% in the 4th quarter. Spire Wealth Management now owns 2,558 shares of the company's stock valued at $32,000 after acquiring an additional 1,023 shares during the last quarter. Transamerica Financial Advisors LLC increased its stake in Amneal Pharmaceuticals by 541.9% in the fourth quarter. Transamerica Financial Advisors LLC now owns 2,914 shares of the company's stock worth $37,000 after purchasing an additional 2,460 shares during the period. Finally, Comerica Bank lifted its position in shares of Amneal Pharmaceuticals by 186.7% during the third quarter. Comerica Bank now owns 3,005 shares of the company's stock worth $30,000 after purchasing an additional 1,957 shares during the last quarter. Hedge funds and other institutional investors own 31.82% of the company's stock.

Amneal Pharmaceuticals News Roundup

Here are the key news stories impacting Amneal Pharmaceuticals this week:

• Positive Sentiment: Q2 results exceeded expectations. Amneal reported revenue of approximately $796 million, GAAP net income of $58 million, adjusted EBITDA of $206 million and adjusted diluted EPS of $0.30, above the $0.24 analyst consensus and up from $0.25 a year earlier. Amneal Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Full-year revenue guidance was raised. Management now expects 2026 revenue of $3.1 billion to $3.2 billion, compared with a prior outlook near $3.1 billion, suggesting continued confidence in demand and operating performance. AMRX Down Despite Q2 Earnings Beat, 2026 Revenue Outlook Raised
• Positive Sentiment: Debt repricing should reduce interest expense. The company completed a July debt repricing, which is expected to lower borrowing costs and support future earnings and cash flow. Amneal Reports Second Quarter 2026 Financial Results
• Neutral Sentiment: EPS guidance was broadly in line with consensus. Amneal forecast 2026 EPS of $0.96 to $1.06 versus the $0.97 consensus estimate. While the midpoint is slightly above expectations, the range does not represent a major upward revision.
• Negative Sentiment: Investors may be taking profits after the earnings-driven rally. The strong quarterly beat and revenue outlook improvement were likely already reflected in the stock after its recent advance, leaving limited upside when full-year earnings guidance was only modestly better than expectations. Amneal beats expectations in strong Q2 2026

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on AMRX. Barclays boosted their target price on shares of Amneal Pharmaceuticals from $15.00 to $16.00 and gave the company an "overweight" rating in a research note on Wednesday, May 20th. UBS Group lifted their price objective on shares of Amneal Pharmaceuticals from $19.00 to $23.00 and gave the company a "buy" rating in a report on Wednesday, July 15th. Weiss Ratings raised shares of Amneal Pharmaceuticals from a "hold (c+)" rating to a "buy (b-)" rating in a research report on Wednesday. Wall Street Zen raised Amneal Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Sunday, July 12th. Finally, The Goldman Sachs Group reiterated a "buy" rating and set a $21.00 target price on shares of Amneal Pharmaceuticals in a report on Friday. Seven investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $17.33.

Amneal Pharmaceuticals Stock Performance

Shares of AMRX stock opened at $18.32 on Monday. The company has a debt-to-equity ratio of 77.65, a current ratio of 2.20 and a quick ratio of 1.44. Amneal Pharmaceuticals, Inc. has a 1 year low of $7.66 and a 1 year high of $19.26. The firm has a market capitalization of $5.84 billion, a price-to-earnings ratio of 37.39 and a beta of 1.27. The business has a fifty day moving average of $16.23 and a 200 day moving average of $14.27.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last issued its earnings results on Thursday, May 7th. The company reported $0.27 EPS for the quarter. The firm had revenue of $722.52 million for the quarter. Amneal Pharmaceuticals had a negative return on equity of 584.46% and a net margin of 5.05%. As a group, research analysts expect that Amneal Pharmaceuticals, Inc. will post 0.92 earnings per share for the current year.

Insiders Place Their Bets

In other Amneal Pharmaceuticals news, Director Deborah M. Autor sold 34,819 shares of Amneal Pharmaceuticals stock in a transaction on Monday, May 11th. The shares were sold at an average price of $12.94, for a total transaction of $450,557.86. Following the sale, the director owned 93,660 shares of the company's stock, valued at $1,211,960.40. The trade was a 27.10% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 17.30% of the company's stock.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.

Want to see what other hedge funds are holding AMRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source